Table 1.

Characteristics of NPM1 MN, NPM1+ MN, and NPM1+ AML cohorts

NPM1 MN (n = 95)NPM1+ MN (n = 45)NPM1+ AML (n = 119)
Patient characteristics
 Median age (range), y68 (38-84)*63 (36-96)61 (15-85)
 Male:female1.91.00.75
Clinical parameters
 Hemoglobin, median (range), g/dL9.7 (4.8-15.9)9.0 (6.1-12.7)9.0 (5.7-15)
 WBC, median (range), ×109/L3.5 (0.6-69.4)3.3 (1.2-225)21 (0.69-340)*
 Platelet count, median (range), ×109/L84 (15-808)79 (15-607)72 (10-356)
 Median of BM cellularity (range), %70 (10-95)80 (10-100)90 (30-98)*
 Median of BM blasts (range), %8 (1-18)10 (1-19)73 (21-96)*
Diagnosis, n (%)
 MDS non-EB5 (5)2 (4)NA
 MDS-EB55 (58)24 (53)NA
 CMML16 (17)9 (20)NA
 MDS/MPN (non-CMML)8 (8)5 (11)NA
 t-MN11 (12)5 (11)NA
 AMLNANA119 (100)
IPSS-R scores (MDS cases only), median (range)5.0 (1.0-10.0)5.0 (1.5-7.0)NA
Outcome
 Median follow-up time (range), mo19.4 (0.3-57)10 (0.07-70)24 (0.13-125)
 Alive at last follow-up, n (%)53 (56)29 (64)67 (56)
 Progression to AML, n (%)30 (32)20 (44)NA
 Median time to progression (range), mo6.3 (1.7-43)5.2 (0.4-17.5)NA
Received upfront HMA therapy, n (%)55 (58)33 (73)5 (4)
Received upfront induction chemotherapy, n (%)0 (0)3 (7)113 (95)
Received SCT at any time, n (%)44 (46)19 (42)67 (56)
  • BM, bone marrow; EB, excess blasts; NA, not available; t-MN, therapy-related myeloid neoplasm.

  • * P < .05 for difference in comparison with NPM1+ MN group (Mann-Whitney U test).